Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05020496 · ClinicalTrials.gov registry record · Early Phase 1
Trem-1 and Ultraviolet Radiation-induced Immune Suppression
A Early Phase 1 study of Skin Diseases, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- Early Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT05020496 is a Early Phase 1 study of Skin Diseases that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 70 participants, below the 205-participant average among 14 other Skin Diseases trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05020496, a Early Phase 1 study of Skin Diseases, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this study is to determine novel mechanisms for ultraviolet light (UV)-induced suppression of the immune system in human subjects and to improve understanding of UV-induced skin carcinogenesis.
Conditions Studied
Interventions
- DRUG Diphenylcyclopropenone (DPCP)
Study Locations (1)
Alabama
- Whitaker Clinic - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2022-03-21 |
| Est. Completion | 2026-10-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05020496
The ClinicalTrials.gov registry entry for NCT05020496 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 14 other Skin Diseases trials with a reported enrollment target (66% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Skin Diseases appearing as the primary indexed condition, and to 1 intervention - of which Diphenylcyclopropenone (DPCP) is the first listed.
NCT05020496 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT05020496 about?
NCT05020496 is a clinical study titled "Trem-1 and Ultraviolet Radiation-induced Immune Suppression". The overall goal of this study is to determine novel mechanisms for ultraviolet light (UV)-induced suppression of the immune system in human subjects and to improve understanding of UV-induced skin carcinogenesis.
What is the current status of trial NCT05020496?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 70 participants. The study started on 2022-03-21. Estimated completion is 2026-10-01.
What conditions does trial NCT05020496 study?
This clinical trial studies the following conditions: Skin Diseases.
What interventions are being tested in trial NCT05020496?
The interventions under investigation include: Diphenylcyclopropenone (DPCP) (DRUG).
Who is sponsoring clinical trial NCT05020496?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05020496 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders
RECRUITING · Early Phase 1
-
OCT Vibrography for Biomechanical Properties of Tissues
RECRUITING · NA
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
RECRUITING · Phase 2
-
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
RECRUITING · Phase 3
-
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.